Bristol-Myers Squibb And Bayer Keep The Focus On China: Emerging Markets Earnings Roundup (Part 2)
This article was originally published in PharmAsia News
Executive Summary
During Q1, BMS welcomed its new R&D president and also saw new products launched in China, while Bayer’s mature products reported strong growth in China.
You may also be interested in...
Eliquis, Bydureon Launches Still A Wait-And-See Story For Bristol
Investors are focused on the launch of both drugs, which are expected to contribute meaningfully to Bristol’s return to growth, as well as on nivolumab, a promising anti-PD-1 in development for cancer. Few conclusions can be drawn on any of those fronts from the company’s first quarter financial update.
Incoming Bristol R&D Chief Cuss Initially Plans To Follow Sigal’s Course Of Action
Long-time senior VP of R&D Francis Cuss will succeed Elliott Sigal as Bristol’s head of R&D on July 1, following a transition period. In an investor call, Cuss indicated no great change in strategy but acknowledged an ongoing need to evolve corporate thinking and capability.
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.